

# Paul J Clark

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3267663/publications.pdf>

Version: 2024-02-01

71  
papers

1,680  
citations

279798

23  
h-index

302126

39  
g-index

72  
all docs

72  
docs citations

72  
times ranked

2655  
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort. <i>Digestive Diseases and Sciences</i> , 2023, 68, 291-303.	2.3	2
2	Fitting Health Care to People: Understanding and Adapting to the Epidemiology and Health Literacy of People Affected by Viral Hepatitis from Culturally and Linguistically Diverse Migrant Backgrounds. <i>Journal of Immigrant and Minority Health</i> , 2022, 24, 1196-1205.	1.6	4
3	Partnering with support persons and clinicians to improve the health care experiences of patients with cirrhosis. <i>Journal of Clinical Nursing</i> , 2022, , .	3.0	1
4	Targeted antiviral treatment of hepatitis B virus in culturally and linguistically diverse populations to achieve elimination targets in Australia. <i>Journal of Viral Hepatitis</i> , 2022, 29, 868-878.	2.0	2
5	Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up. <i>BMC Gastroenterology</i> , 2022, 22, .	2.0	2
6	Hepatocellular carcinoma in Indigenous Australians: a call to action. <i>Medical Journal of Australia</i> , 2021, 214, 201.	1.7	6
7	The Patient's Perspective in Cirrhosis: Unmet Supportive Care Needs Differ by Disease Severity, Etiology, and Age. <i>Hepatology Communications</i> , 2021, 5, 891-905.	4.3	8
8	Remoteness of residence predicts tumor stage, receipt of treatment, and mortality in patients with hepatocellular carcinoma. <i>JGH Open</i> , 2021, 5, 754-762.	1.6	1
9	Hepatocellular carcinoma amongst Aboriginal and Torres Strait Islander peoples of Australia. <i>EClinicalMedicine</i> , 2021, 36, 100919.	7.1	14
10	Eliminating hepatitis C in Australia needs informed patients and enabled GPs. <i>Medical Journal of Australia</i> , 2021, 215, 318-319.	1.7	1
11	1204Modelling impact of targeted hepatitis B treatment for culturally and linguistically diverse populations in Australia. <i>International Journal of Epidemiology</i> , 2021, 50, .	1.9	0
12	1203Predictors of treatment and survival in hepatocellular carcinoma patients: A Bayesian parametric survival analysis. <i>International Journal of Epidemiology</i> , 2021, 50, .	1.9	0
13	Disparities in Unmet Needs in Indigenous and Non-Indigenous Australians with Cirrhosis: An Exploratory Study. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2649-2658.	1.8	3
14	Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 171.	2.8	139
15	Hospitalisation for cirrhosis in Australia: disparities in presentation and outcomes for Indigenous Australians. <i>International Journal for Equity in Health</i> , 2020, 19, 27.	3.5	14
16	&lt;p&gt;Development and Evaluation of the Supportive Needs Assessment Tool for Cirrhosis (SNAC)&lt;/p&gt;. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 599-611.	1.8	18
17	Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations. <i>Proteomics - Clinical Applications</i> , 2019, 13, 1800006.	1.6	1
18	Increasing Hospitalization Rates for Cirrhosis: Overrepresentation of Disadvantaged Australians. <i>EClinicalMedicine</i> , 2019, 11, 44-53.	7.1	39

#	ARTICLE	IF	CITATIONS
19	Optimising Hepatitis C care in an urban Aboriginal and Torres Strait Islander primary health care clinic. <i>Australian and New Zealand Journal of Public Health</i> , 2019, 43, 228-235.	1.8	4
20	Five-year conditional survival for patients with hepatocellular carcinoma in Queensland, Australia. <i>GastroHep</i> , 2019, 1, 61-69.	0.6	0
21	More needs to be spent on hepatitis C treatment, not less. <i>Internal Medicine Journal</i> , 2018, 48, 364-366.	0.8	0
22	Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey. <i>Future Oncology</i> , 2018, 14, 1701-1710.	2.4	26
23	Projections of primary liver cancer to 2030 in 30 countries worldwide. <i>Hepatology</i> , 2018, 67, 600-611.	7.3	219
24	Bilirubin acts as a multipotent guardian of cardiovascular integrity: more than just a radical idea. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 315, H429-H447.	3.2	51
25	Evaluation of a bone morphogenetic protein 6 variant as a cause of iron loading. <i>Human Genomics</i> , 2018, 12, 23.	2.9	8
26	Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia. <i>Internal Medicine Journal</i> , 2017, 47, 429-435.	0.8	21
27	Hepatitis C in Australia – a role for general practitioners?. <i>Medical Journal of Australia</i> , 2017, 207, 53-53.	1.7	16
28	Liver-related mortality in countries of the developed world: an ecological study approach to explain the variability. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 68-77.	3.7	9
29	Use of telehealth to treat and manage chronic viral hepatitis in regional Queensland. <i>Journal of Telemedicine and Telecare</i> , 2016, 22, 459-464.	2.7	17
30	Serum markers for hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2016, 8, 29-33.	2.1	11
31	Hepatobiliary and Pancreatic: Acute hepatitis in the setting of chronic <i>Schistosoma mansoni</i> infection and post-praziquantel therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 910-910.	2.8	1
32	Tu1690 Liver-Related Mortality in Countries of the Developed World: An Ecological Study Approach to Explain the Variability. <i>Gastroenterology</i> , 2016, 150, S926.	1.3	0
33	Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. <i>Journal of Hepatology</i> , 2016, 64, 29-36.	3.7	30
34	Remoteness, race and social disadvantage: disparities in hepatocellular carcinoma incidence and survival in Queensland, Australia. <i>Liver International</i> , 2015, 35, 2584-2594.	3.9	24
35	Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease. <i>BMJ Open</i> , 2015, 5, e007451-e007451.	1.9	59
36	Enhancing hepatitis C treatment in the custodial setting: a national roadmap. <i>Medical Journal of Australia</i> , 2014, 200, 15-16.	1.7	11

#	ARTICLE	IF	CITATIONS
37	The Association of IL28b Genotype with the Histological Features of Chronic Hepatitis C Is HCV Genotype Dependent. <i>International Journal of Molecular Sciences</i> , 2014, 15, 7213-7224.	4.1	19
38	Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication. <i>Clinical Science</i> , 2014, 126, 845-855.	4.3	22
39	Trends in hepatitis C treatment uptake in the United States. <i>Hepatology</i> , 2014, 60, 768-769.	7.3	3
40	Hepatitis C Virus. , 2014, , 859-877.		0
41	Recurrence of Hepatocellular Carcinoma: Importance of mRECIST Response to Chemoembolization and Tumor Size. <i>American Journal of Transplantation</i> , 2014, 14, 1383-1390.	4.7	75
42	Association between hypermethylation of DNA repetitive elements in white blood cell DNA and pancreatic cancer. <i>Cancer Epidemiology</i> , 2014, 38, 576-582.	1.9	18
43	Predictors of consent to pharmacogenomics testing in the IDEAL study. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 619-623.	1.5	3
44	Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. <i>Journal of Viral Hepatitis</i> , 2013, 20, 858-866.	2.0	32
45	Overcoming Barriers to Care for Hepatitis C. <i>New England Journal of Medicine</i> , 2012, 366, 2436-2438.	27.0	26
46	Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia in HIV/HCV-Coinfected Patients With All HCV Genotypes. <i>Journal of Infectious Diseases</i> , 2012, 205, 376-383.	4.0	31
47	Systemic thrombolysis for acute, severe Budd-Chiari syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 410-415.	2.1	11
48	Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2012, 56, 313-319.	3.7	39
49	Reply to "IL28B polymorphism and hepatitis C: A genetic marker of peginterferon- $\alpha$ sensitivity devoid from classical interferon- $\alpha$ side effects?" <i>Journal of Hepatology</i> , 2012, 56, 742-743.	3.7	0
50	The Association of Genetic Variants with Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C Infection. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2213-2221.	2.3	25
51	Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. <i>Hepatology</i> , 2012, 56, 49-56.	7.3	67
52	Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: Impaired viral kinetics and therapeutic response. <i>Hepatology</i> , 2012, 56, 444-454.	7.3	61
53	Lost in translation? IL28B's discovery and the journey back to the patient. <i>Hepatology</i> , 2012, 56, 5-8.	7.3	3
54	Host genomics and HCV treatment response. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 212-222.	2.8	29

#	ARTICLE	IF	CITATIONS
55	Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. <i>Journal of Viral Hepatitis</i> , 2012, 19, 278-282.	2.0	29
56	Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL) in genotype 1 chronic hepatitis C and determine the association between LDL and treatment response. <i>Journal of Viral Hepatitis</i> , 2012, 19, 332-340.	2.0	34
57	IL28B Genomic-Based Treatment Paradigms for Patients With Chronic Hepatitis C Infection: The Future of Personalized HCV Therapies. <i>American Journal of Gastroenterology</i> , 2011, 106, 38-45.	0.4	80
58	Thyroid Stimulating Hormone (TSH) and Peginterferon Treatment Induced Hypothyroidism May Be Associated With Phosphodiesterase Polymorphisms in Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2011, 140, S-891.	1.3	0
59	Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2011, 55, 1195-1200.	3.7	81
60	Noninvasive tools to assess liver disease. <i>Current Opinion in Gastroenterology</i> , 2011, 27, 210-216.	2.3	18
61	Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1182-1188.	2.8	18
62	IL28B Polymorphisms and Treatment of Hepatitis C. <i>Current Hepatitis Reports</i> , 2011, 10, 70-78.	0.3	0
63	Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. <i>Hepatology</i> , 2011, 53, 389-395.	7.3	67
64	Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. <i>Hepatology</i> , 2011, 54, 1559-1569.	7.3	65
65	Characterization of Serum Proteins Associated with IL28B Genotype among Patients with Chronic Hepatitis C. <i>PLoS ONE</i> , 2011, 6, e21854.	2.5	18
66	Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. <i>Hepatology</i> , 2010, 52, 2243-2244.	7.3	28
67	Hepatitis C virus nonstructural protein 5A inhibitors: Novel target-Now for new trials and new treatment strategies. <i>Hepatology</i> , 2010, 52, 1162-1164.	7.3	0
68	Genetic Variation in IL28B: Impact on Drug Development for Chronic Hepatitis C Infection. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 708-711.	4.7	9
69	Utility of eosinophilia as a diagnostic clue in lower abdominal pain in northern Australia: a retrospective case-control study. <i>Internal Medicine Journal</i> , 2008, 38, 278-280.	0.8	4
70	Resolution of Protein-Losing Enteropathy After Successful Heart Transplantation in an Adult Patient With Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC). <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 963-964.	0.6	2
71	Protecting persons at-risk of viral hepatitis and alcohol-related liver disease during the pandemic and beyond: mitigating the impact of coronavirus disease 2019 on liver health. <i>Journal of Global Health Reports</i> , 0, , .	1.0	1